{"gao_id": "GAO-20-617", "published": "2020-08-04T12:00:00Z", "released": "2020-08-04T08:00:00Z", "summary": "Treatment for opioid use disorder may involve buprenorphine\u2014a drug that can reduce or eliminate withdrawal symptoms and prevent relapse. We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disorder. These forms release the drug over 1- or 6-month periods respectively. Providers issued about 7,250 prescriptions for injectable or implantable buprenorphine in FY 2019. Providers and pharmacy representatives said there...", "title": "Opioid Use Disorder: Treatment with Injectable and Implantable Buprenorphine", "topics": ["Patient care", "Prescription drugs", "Pharmacy", "Addiction", "Drug addiction", "Health Care", "Drug enforcement", "Controlled substances", "Drugs", "Substance abuse treatment", "Substance abuse"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-617", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-617-highlights.pdf"}, {"title": "Full Report (21 pages)", "url": "https://www.gao.gov/assets/gao-20-617.pdf"}, {"title": "Accessible PDF (24 pages)", "url": "https://www.gao.gov/assets/710/708740.pdf"}]}